The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1525
ISSUE 1525
July 17, 2017
Drugs for Helicobacter pylori Infection
| The full article is available to subscribers | Subscriber Login |
July 17, 2017 (Issue: 1525)
About 50% of the world’s population is infected with Helicobacter pylori. These gastric bacteria can cause chronic inflammation and have been associated with development of gastritis, peptic ulcer disease, gastric adenocarcinoma, and gastric mucosa-associated lymphoid tissue (MALT) lymphoma.1 Eradication of H. pylori can promote gastric healing, prevent recurrence of duodenal and gastric ulcers, and reduce the incidence of gastric cancer.2,3 Guidelines for treatment of H. pylori infection were updated recently.4-6
NONINVASIVE TESTING — Urea Breath Tests – A urea breath test (BreathTek; BreathID; PYtest) can be used for office-based diagnosis of H. pylori infection. The patient ingests a urea solution or urea-containing capsule labeled with a carbon
... more- EA Marcus et al. Eradication of Helicobacter pylori infection. Curr Gastroenterol Rep 2016; 18:33.
- Drugs for peptic ulcer disease and GERD. Treat Guidel Med Lett 2014; 12:25.
- YC Lee et al. Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis. Gastroenterology 2016; 150:1113.
- CA Fallone et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology 2016; 151:51.
- WD Chey et al. ACG Clinical Guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol 2017; 112:212.
- P Malfertheiner et al. Management of Helicobacter pylori infection – the Maastricht V/Florence Consensus Report. Gut 2017; 66:6.
- MP Dore et al. Dyspepsia: when and how to test for Helicobacter pylori infection. Gastroenterol Res Pract 2016 April 28 (epub).
- S Shiota et al. Antibiotic resistance of Helicobacter pylori among male United States veterans. Clin Gastroenterol Hepatol 2015; 13:1616.
- PY Chen et al. Systematic review with meta-analysis: the efficacy of levofloxacin triple therapy as the first- or second-line treatments of Helicobacter pylori infection. Aliment Pharmacol Ther 2016; 44:427.
- M Venerito et al. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. Digestion 2013; 88:33.
- JP Gisbert and X Calvet. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol 2012; 5:23.
- J Molina-Infante et al. Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study. Aliment Pharmacol Ther 2015; 41:581.
- JM Liou et al. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 2016; 388:2355.
- PP Basu et al. A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. Am J Gastroenterol 2011; 106:1970.
- E Coss et al. Sequential therapy is not better at eradication of primary Helicobacter pylori infection when compared to standard triple therapy in the United States–a prospective, randomized evaluation in a United States population. Gastroenterology 2014; 146:S399. Abstract Su1194.
- OP Nyssen et al. Sequential versus standard triple first-line therapy for Helicobacter pylori eradication. Cochrane Database Syst Rev 2016; 6:CD009034.
- AG McNicholl et al. Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. Gut 2014; 63:244.
- SD Georgopoulos et al. Randomized clinical trial comparing ten day concomitant and sequential therapies for Helicobacter pylori eradication in a high clarithromycin resistance area. Eur J Intern Med 2016; 32:84.
- PB Kale-Pradhan et al. Fluoroquinolone sequential therapy for Helicobacter pylori: a meta-analysis. Pharmacotherapy 2015; 35:719.
- B Wang et al. Review: efficacy and safety of hybrid therapy for Helicobacter pylori infection: a systematic review and meta-analysis. Helicobacter 2015; 20:79.
- Probiotics revisited. Med Lett Drugs Ther 2013; 55:3.
- LV McFarland et al. Systematic review and meta-analysis: multi-strain probiotics as adjunct therapy for Helicobacter pylori eradication and prevention of adverse events. United European Gastroenterol J 2016; 4:546.
- MM Zhang et al. Probiotics in Helicobacter pylori eradication therapy: a systematic review and meta-analysis. World J Gastroenterol 2015; 21:4345.
- Y Yuan et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev 2013; 12:CD008337.
- AC Marin et al. Efficacy of a second-line levofloxacin-containing triple therapy after the failure of the non-bismuth sequential or concomitant treatments: systematic review and meta-analysis. Helicobacter 2014; 19 (Suppl 1):139, abstract P11.39.
- AC Marin et al. A review of rescue regimens after clarithromycincontaining triple therapy failure (for Helicobacter pylori eradication). Expert Opin Pharmacother 2013; 14:843.
- T Shaikh and CA Fallone. Effectiveness of second through sixth line salvage Helicobacter pylori treatment: bismuth quadruple therapy is almost always a reasonable choice. Can J Gastroenterol Hepatol 2016 March 29 (epub).
- JP Gisbert et al. Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures. Aliment Pharmacol Ther 2012; 35:941.
- J Molina-Infante and A Shiotani. Practical aspects in choosing Helicobacter pylori therapy. Gastroenterol Clin North Am 2015; 44:519.
- C Giuliano et al. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. Expert Rev Clin Pharmacol 2012; 5:337.
- M Sarkar et al. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med 2008; 149:391.
- KB Filion et al. Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis. Gut 2014; 63:552.
- AD Leonard et al. Proton pump inhibitors and diarrhoea related to Clostridium difficile infection in hospitalised patients: a case-control study. Intern Med J 2012; 42:591.
- DL McCollum and JM Rodriguez. Detection, treatment, and prevention of Clostridium difficile infection. Clin Gastroenterol Hepatol 2012; 10:581.
- CS Kwok et al. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: a meta-analysis. Am J Gastroenterol 2012; 107:1011.
- Inhibitors and inducers of CYP enzymes and p-glycoprotein. Med Lett Drugs Ther 2017. May 18 (epub). Available at: medicalletter. org/downloads/CYP_PGP_Tables.pdf. Accessed June 29, 2017.
- RL Woosley and KA Romero. QT drugs list. Available at: www. crediblemeds.org. Accessed June 29, 2017.
- Drug interaction: clopidogrel and PPIs. Med Lett Drugs Ther 2017; 59:39.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Immediate Online access to current issue and archives from 1988 to the present
- Mobile access to our mobile site and free apps for iOS, Android and Kindle
- FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Drugs for Helicobacter pylori Infection
Article code: 1525a
Electronic, downloadable article - $25
Article code: 1525a
Electronic, downloadable article - $25
